Skin Cancer Melanoma Medical Oncology
Sapna Patel, MD, a widely renowned melanoma oncologist and clinical investigator, has joined the University of Colorado Cancer Center and the CU Department of Medicine, with a goal of helping to build a “pinnacle of skin cancer treatment” in the Rocky Mountains.
Research Lung Cancer Radiation Medical Oncology Targeted Therapies
It’s been a dozen years since D. Ross Camidge, MD, PhD, of the University of Colorado Cancer Center and his colleagues first published on the use of tightly-focused radiation to attack isolated active cancer sites in lung cancer patients who otherwise were responding well to targeted therapies. In the years since, that breakthrough has transformed cancer care.
Research Lung Cancer Medical Oncology
Combining targeted therapies known as tyrosine kinase inhibitors (TKIs) can be an effective way to treat a mutation-driven form of lung cancer in cases where tumors develop resistance to treatment and where cancer has spread to other parts of the body, a University of Colorado Cancer Center member reports.
Research Breast Cancer Drug Development Medical Oncology
Research led by University of Colorado Cancer Center members points to a combination of drugs as a potential treatment option for a type of aggressive breast cancer.
Research Head and Neck Cancer Medical Oncology
After eight years of work by a pair of University of Colorado Cancer Center leaders on a new way to attack various cancers, the next stage in their quest to bring their therapy to patients is one of nine research endeavors receiving funding from the Anschutz Acceleration Initiative (AAI).
Cancer Magazine Multidisciplinary Clinic Medical Oncology
A cancer diagnosis is a serious matter – which is why a patient who gets one should seriously consider getting a second opinion.
Research Breast Cancer Medical Oncology
The focus of a University of Colorado Cancer Center member’s research career has been a quest for new, better therapies for patients with breast cancer. That quest by Elena Shagisultanova, MD, PhD, has resulted in a clinical trial pointing the way to an oral treatment that’s more tolerable than intensive chemotherapy for patients with a type of metastatic breast cancer that accounts for about 20% of cases among women under age 45.
Cure Today
July 12, 2024
University of Colorado Cancer Center member Dr. Steven Thorpe emphasizes the collaborative nature of treating soft tissue and bone sarcomas, highlighting the multidisciplinary efforts at CU School of Medicine's Department of Orthopedics and Children’s Hospital Colorado. He underscores the goal of not only curing the disease but also preserving function through advanced surgical techniques and modern therapies, ensuring patients maintain quality of life post-treatment. Thorpe stresses the importance of long-term outcomes, tailoring treatments to support patients’ aspirations beyond their cancer journey, especially for pediatric cases.
OncLive
July 08, 2024
CU Cancer Center member S. Lindsey Davis, MD, highlighted that the combination therapy of sapanisertib and alisertib showed marginal clinical benefit for patients with advanced solid tumors, correlative analyses suggested that apoptotic response and tumor immune cell infiltrate might influence clinical outcomes. The phase 1b study's expansion cohort indicated some positive outlying responses among patients and underscore the need for further research to tailor treatments for standout patients and explore rational combinations to enhance efficacy.
News Medical
June 19, 2024
A new study led by University of Colorado Cancer Center member Marco Del Chiaro, MD, PhD, reveals that nearly 5% of pancreatic adenocarcinoma patients achieved a pathological complete response (pCR) after pre-surgical chemotherapy or chemoradiotherapy. This significant finding indicates that patients with pCR have a 63% five-year survival rate, compared to 30% for those without pCR, suggesting the potential for tailored treatments to improve outcomes.
Cancer Network
June 14, 2024
In a conversation at the 2024 European Hematology Association Congress, CU Cancer Center member Manali Kamdar, MD, discussed potential future research on lisocabtagene maraleucel (liso-cel; Breyanzi) for mantle cell lymphoma (MCL) and other lymphoma subgroups. She highlighted findings from the phase 1 TRANSCEND NHL 001 trial, noting improved efficacy and safety in patients with fewer prior therapies and non-refractory disease, suggesting liso-cel's utility in earlier treatment lines and specific lymphoma subgroups.
Mark Harden
